Last updated: 2026-09-05 02:18:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $827.55, with a market capitalization of $87.72B and a P/E ratio of 20.06. Over the past 52 weeks, its price has ranged from $541.00 to $859.34. This page covers its latest market performance, valuation, price trends and company information.
$87.72B | |
$840.06 | |
$1,211.20 | |
$4.61 | |
$843.47 | |
303.69K | |
-- | |
20.06 | |
$859.34 | |
$541.00 | |
0.44% | |
-- |
Regeneron Pharmaceuticals Inc. (REGN) last closed at $843.47 as of 2026-09-04 23:58:00, unchanged from the previous close of $843.47.
During the latest regular trading session, REGN traded between $4.61 and $1,211.20, with a volume of 303.69K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $782.44 to $827.55, representing a gain of 5.76% ($45.11).
The stock traded between $826.71 and $845.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 662.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.0%
REGN is currently trading at $827.55, placing it 90.0% of the way from its 52-week low of $541.00 to its 52-week high of $859.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15410 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.